Gonorrhoea Market Size was approximately USD XX Million in 2022, estimates DelveInsight

"The Gonorrhoea Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Gonorrhoea pipeline products will significantly revolutionize the Gonorrhoea market dynamics"

The Gonorrhoea market report provides current treatment practices, Gonorrhoea emerging drugs, market share of individual therapies, and current and forecasted 7MM a Gonorrhoea market size from 2019 to 2032. The report also covers current Gonorrhoea treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Key Takeaways from the Gonorrhoea Market Research Report
• According to several secondary sources, Gonorrhoea is more common in males than in females.
• The key driver for the surge in Gonorrhoea market size is the high incidence of the disease, and increasing awareness in the 7MM.
• The leading companies working in the Gonorrhoea Market include Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals, and others.
• Promising Gonorrhoea Pipeline Therapies in the various stages of development include Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, solithromycin, and others.
• March 2023: GlaxoSmithKline announced a study of Phase 3 clinical trials for Gepotidacin, Ceftriaxone, and Azithromycin. This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae (N. gonorrhoeae) in adolescent and adult participants. In this study, participants will be randomly assigned to receive either oral gepotidacin or IM ceftriaxone plus oral azithromycin.
• August 2023: GlaxoSmithKline announced a study of Phase 2 clinical trials for NgG HTD investigational vaccine. The aim of this first time in human proof of concept (FTiH-PoC) study is to evaluate safety and reactogenicity, to demonstrate efficacy and to explore immunogenicity of GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine compared to placebo (saline).

Discover more about therapies set to grab major Gonorrhoea Market Share @ Gonorrhoea Market Size- https://www.delveinsight.com/report-store/gonorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gonorrhoea Overview
Gonorrhoea is a sexually transmitted infection caused by the Neisseria gonorrhoeae. It tends to infect warm and moist areas of the body like urethra, eyes, throat, anus, vagina and female reproductive tract. Gonorrhoea is transmitted through sexual contact including sex without using a condoom, vaginal intercourse, anal and ooral seex. The infection can also be transmitted from mother-to-child during childbirth.

Gonorrhoea Epidemiology Segmentation in the 7MM
• Total Gonorrhoea Incident Cases
• Gonorrhoea Age-specific Incident Cases
• Gonorrhoea Gender-specific Incident Cases
• Gonorrhoea Treatable Cases

Download the report to understand which factors are driving Gonorrhoea Epidemiology Trends @ Gonorrhoea Epidemiological Insights- https://www.delveinsight.com/sample-request/gonorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gonorrhoea Market Insights
The primary characteristic of the monotherapy segment is the utilization of a single drug to treat a given disease. This segment is primarily comprised of the administration of either oral cefixime or intramuscular (IM) ceftriaxone for the treatment of gonorrhoea. One of the key advantages of this segment, which drives its adoption, is the low incidence of side effects due to the use of a single drug.

Gonorrhoea Market Landscape
The current pipeline of Gonorrhoea consists of few drugs and vaccines, such as GSK2140944 (gepotidacin), GSK4348413 and others. So there is a wide opportunities available for key market players to enter the market. Ongoing awareness and research may increase the market.

To know more about Gonorrhoea Treatment options, visit @ Gonorrhoea Drugs- https://www.delveinsight.com/sample-request/gonorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gonorrhoea Emerging Therapy Assessment
The emerging pipeline of Gonorrhoea is not very robust. There are few potential emerging therapies upcoming for Gonorrhoea, the major key players include GlaxoSmithKline, and others.

Gonorrhoea Treatment Market
The Gonorrhoea Treatment Market has witnessed significant growth and innovation in recent years, driven by the rising prevalence of Gonorrhoea infections worldwide. As one of the most common sexually transmitted infections, Gonorrhoea poses a serious public health threat, necessitating continuous advancements in treatment options. The market is characterized by a plethora of research and development activities, leading to the introduction of novel therapies and medications.

Learn more about the Gonorrhoea Pipeline Therapies in clinical trials @ Gonorrhoea Market Landscape- https://www.delveinsight.com/sample-request/gonorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Gonorrhoea Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Gonorrhoea Companies- Evofem Biosciences, GlaxoSmithKline, Entasis Therapeutics, Alopexx Pharmaceuticals, Nobelex Biotech, Summit Therapeutics, TherapyX, AchilleS Vaccines, Recce Pharmaceuticals, VenatoRx Pharmaceuticals, and others.
• Gonorrhoea Pipeline Therapies- Gepotidacin, Ceftriaxone, Azithromycin, GSK2140944, solithromycin, and others.
• Gonorrhoea Market Dynamics: Gonorrhoea Market Drivers and Barriers

Discover more about Gonorrhoea Drugs in development @ Gonorrhoea Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/gonorrhea-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Gonorrhoea Executive Summary
3. Competitive Intelligence Analysis
4. Gonorrhea Market Overview at a Glance
5. Gonorrhea Market Disease Background and Overview
6. Patient Journey
7. Gonorrhea Epidemiology and Patient Population
9. Gonorrhea Unmet Needs
10. Key Endpoints of Gonorrhea Treatment
11. Gonorrhea Marketed Products
12. Gonorrhea Emerging Therapies
13. Gonorrhea: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Gonorrhoea Market Outlook
16. Gonorrhoea Market Access and Reimbursement Overview
17. KOL Views
18. Gonorrhoea Market Drivers
19. Gonorrhoea Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.